Meeting
2021 ASCO Annual Meeting
Complementary detection of genomic alterations in metastatic castration‑resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.
Authors
Mark Sausen
Bristol Myers Squibb, Princeton, NJ
Mark Sausen , Jonathan F. Baden , Natallia Kalinava , Xuya Wang , Jun Li , Esperanza Anguiano , Keziban Unsal-Kacmaz , Megan Wind-Rotolo , Katie Quinn , George Green
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03338790
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5038)
DOI
10.1200/JCO.2021.39.15_suppl.5038
Abstract #
5038
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Justin Shaya
Poster
2019 ASCO Annual Meeting
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer.
First Author: Raanan Alter
Poster
2019 ASCO Annual Meeting
Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 CSPC): A pilot molecular analysis in the STAMPEDE multi-center clinical trial.
First Author: Clare Gilson
Poster
2019 Genitourinary Cancers Symposium
Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Marcus Marie Moses